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Abstract 
Background: Ilex latifolia Thunb. (Da Ye Dong Qing) is used for weight loss and for its antidiabetic effects. This study 
aims to investigate the beneficial effects and potential mechanisms of action of crude triterpenoid saponins (CTS) 
from I. latifolia in a mouse model of high‑fat diet (HFD)‑induced non‑alcoholic fatty liver disease (NAFLD).
Methods: Male C57BL/6 mice (n = 50), were arbitrarily divided into five groups (n = 10 in each group): a control 
group, HFD group, simvastatin group (10 mg/kg/day), and two CTS treatment groups (100 and 200 mg/kg/day). All 
mice except those in the control group were fed an HFD for 4 weeks. Animals in the treatment groups were orally 
administered simvastatin or CTS for 8 weeks. Oral glucose tolerance tests and insulin tolerance tests were performed. 
At the end of treatment, plasma lipid levels, and oxidative parameters in the liver were measured using commercial 
test kits. Western blotting was used to evaluate whether CTS induced AMP‑activated protein kinase (AMPK) and acetyl 
CoA carboxylase activation, and the expression of transcription factors and their target genes was evaluated in a 
quantitative PCR assay.
Results: Compared with the HFD group, the CTS (200 mg/kg/day) treatment group showed significantly decreased 
plasma lipid parameters (P < 0.001, P = 0.018, and P = 0.005 for triglycerides, total cholesterol and low‑density 
lipoprotein cholesterol, respectively), and improved insulin resistance (P = 0.006). CTS (100 and 200 mg/kg/day) 
supplementation also reduced hepatic lipids and protected the liver from oxidative stress by attenuating malondi‑
aldehyde content (P < 0.001 and P < 0.001, respectively) and restoring aspartate aminotransferase levels (P < 0.001 
and P < 0.001, respectively). Moreover, CTS (200 mg/kg/day) reduced lipid accumulation by enhancing AMPK phos‑
phorylation and inhibiting expression of sterol regulatory element‑binding proteins (SREBPs) and their target genes 
SREBP‑1c, SREBP‑2, fatty acid synthase, and stearoyl‑CoA desaturase (P = 0.013, P = 0.007, P = 0.011, and P = 0.014, 
respectively).
Conclusion: CTS from I. latifolia improved insulin resistance and liver injury in HFD‑fed mice, and attenuated NAFLD 
via the activation of AMPK and inhibition of the gene expression of SREBPs and some of their target molecules.
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Background
Non-alcoholic fatty liver disease (NAFLD) is character-
ized by fatty changes in the liver that do not occur as a 
result of alcohol intake. It refers to a wide spectrum of 
conditions involving liver damage, including non-alco-
holic steatohepatitis (NASH), fibrosis, and cirrhosis and 
its complications [1, 2], and is now regarded as a mani-
festation of metabolic syndrome and a shared pathogenic 
factor for obesity, type 2 diabetes mellitus (T2DM), and 
cardiovascular disease [3, 4]. In terms of its pathogenesis, 
excessive fat accumulation in hepatic cells causes oxida-
tive stress in the liver, leading to the development of insu-
lin resistance (IR) [5, 6]. Thus, reducing fat accumulation 
by inhibiting lipogenic synthesis and increasing fat break-
down could be helpful in the prevention and treatment of 
NAFLD.
Many enzymes and transcription factors are involved 
in lipogenesis and are organized into multi-enzyme 
complexes to promote fatty acid synthesis, including 
acetyl CoA carboxylase (ACC), fatty acid synthase (FAS), 
stearoyl-CoA desaturase 1 (SCD-1), and sterol regula-
tory element-binding protein (SREBP) [7, 8]. In the liver, 
SREBP-2 predominantly regulates enzymes associated 
with cholesterol and bile acid synthesis, such as hydrox-
ymethylglutaryl coenzyme A synthase (HMGCS) [9]. 
AMP-activated protein kinase (AMPK) is a serine/thre-
onine protein kinase composed of α, β, and γ subunits, 
and is associated with adipocyte differentiation [10]. Fur-
thermore, increasing evidence indicates an inverse cor-
relation between AMPK and SREBP-1c in hepatocytes 
and the livers of high-fat diet (HFD)-fed or ethanol-fed 
mice [11, 12]. AMPK interacted with and phosphorylated 
SREBP-1c and SREBP-2 to attenuate hepatic steatosis in 
mice with diet-induced IR [13]. Therefore, the regulation 
of AMPK and SREBP may be of key therapeutic impor-
tance in preventing fatty liver disease.
The leaves of Ilex latifolia Thunb. (Da Ye Dong Qing) 
have been widely used to quench thirst, refresh the mind, 
relieve wind-heat (feng-re), and clear toxins from the 
blood (xue); they are also used to treat the common cold, 
obesity, sore throat, rhinitis, itching eyes, and conjuncti-
val congestion [14]. Furthermore, I. latifolia may improve 
hypertension, hyperlipidemia, and other cardiovascular 
diseases [15, 16]. Phytochemical studies have indicated 
that triterpenoids, phenolic acids, flavonoids, and essen-
tial oils are the major constituents of I. latifolia [17–19]. 
Many of these components have potential health benefits 
including antioxidant, anti-obesity, neuro-protective, 
hepatoprotective, and anti-inflammatory effects [20–23]. 
Triterpenoids from I. latifolia were shown to inhibit acyl 
CoA cholesterol acyl transference [24].
This study aims to investigate the beneficial effects and 
potential mechanisms of action of crude triterpenoid 




The leaves of I. latifolia were collected from Wanning, 
Hainan Province, China, and were identified by Prof. 
Guangxiong Zhou, College of Pharmacy, Jinan Univer-
sity, Guangzhou, China. The voucher specimen (No. 
1201209) was deposited at the College of Pharmacy, Jinan 
University.
Chemicals and reagents
Kudinoside O, kudinoside N, kudinoside H, latifolo-
side G, kudinoside G kudinoside C, kudinoside A, kudi-
noside E, kudinoside F, latifoloside Q, kudinoside D, 
and ilekudinoside E were extracted from the leaves of 
I. latifolia using boiling water, separated using D101 
macroporous resin (Yunkai Resin Technology Co., Ltd., 
China) and silica gel column chromatography (Qingdao 
Haiyang Chemical Co., Ltd., China), and purified using 
high performance liquid chromatography (HPLC) col-
umn chromatography (Cosmosil 5C18-MS-II, Nacalai 
Tesque, Japan) and a preparative HPLC system (Agi-
lent 1260, Agilent Technologies, USA). The structures 
of these saponins were determined by comparing their 
spectral (UV, IR, MS, and NMR) data with those in the 
literature [15, 25–27]. Each saponin was dissolved in 
methanol at a concentration of 20 μg/mL. HPLC-grade 
acetonitrile, methanol, and formic acid were purchased 
from Merck (Darmstadt, Germany). Rabbit polyclonal 
antibodies against phospho-AMPKα (Thr172), AMPK, 
phospho-ACC, and ACC were purchased from Cell Sign-
aling Technology (Danvers, MA, USA). All the other 
chemical reagents were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). Normal diets and the HFD were 
purchased from Guangdong Medical Laboratory Animal 
Center (Guangzhou, China). The HFD consisted of 18% 
lard stearin (w/w), 5% egg powder, 1% cholesterol, 20% 
sucrose, 0.1% bile salt, and 55.9% normal diet.
CTS preparation
The leaves of I. latifolia were extracted three times with 
boiling water for 2 h. The extracting solution was applied 
to a D 101 resin column and eluted with H2O, 45% EtOH, 
75% EtOH, and 95% EtOH successively to obtain four 
fractions. Our previous studies, in which we performed 
a chemical analysis of the leaves of I. latifolia using ultra-
high-performance liquid chromatography quadrupole 
time-of-flight mass spectrometry (UPLC-QTOF–MS), 
showed the presence of CTS in the 75% EtOH fractions 
[28]. The 75% EtOH fraction was concentrated and dried 
in a vacuum to obtain the CTS.
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Determination of CTS content
CTS were qualitatively and quantitatively analyzed by 
UHPLC-Q-TOF-MS. The CTS (20 mg) were dissolved in 
100 mL of methanol, and filtered with a 0.22-μm nylon 
filter membrane. The samples were prepared in triplicate. 
The filtrate was then transferred to an auto-sampler vial 
for UHPLC-Q-TOF-MS analysis. The injection volume 
was 2 μL.
UHPLC was performed on a Waters Acquity UHPLC 
system (binary solvent delivery system, auto sam-
pler, and column compartment; Waters, Milford, 
MA, USA), which was coupled with a Waters Xevo 
G2 Q-TOF (Waters). The samples were separated on 
an Agilent Extend C18 RRHD column (2.1 ×  150 mm 
I.D., 1.8 μm). The mobile phase consisted of H2O con-
taining 0.1% formic acid (v/v, solvent A) and acetoni-
trile containing 0.1% formic acid (v/v, solvent B). A 
gradient program was used according to the following 
profile: 0–1  min, 5% B; 1–4  min, 5–25% B; 4–12  min, 
25–40% B; 12–13 min, 40–95% B; and 3-min post-run, 
5% B, flow rate 0.5  mL/min. The column temperature 
was 40°C. The interface was electrospray injection, and 
the acquisition parameters were as follows: capillary 
voltage, 3,500 V; cone voltage, 5 V; source temperature, 
100°C; nebulization gas, 800 L/h at 350°C; cone gas, 50 
L/h; and mass range recorded, m/z 100–15,00. During 
the whole process of analysis, leucine-enkephalin (m/z 
554.2615) served as a reference ion was sampled 0.3  s 
per 5 s. Quantification was performed using the nega-
tive ion mode.
Animals and their treatment
Six-week-old, male C57BL/6J mice (n  =  50, specific 
pathogen-free grade, Certified No. SCXK [Guang-
dong] 2003-0001) were obtained from Guangdong 
Medical Laboratory Animal Center (China). The ani-
mals were kept in a breeding room with controlled 
environment (temperature: 23 ±  1°C, 12  h dark/light 
cycle from 6:00 a.m. to 6:00 p.m.) with free access to 
food and water. After a week of adaptation, the mice 
were arbitrarily divided into five groups (n  =  10/
group) as follows: a control group (Control group), an 
HFD-fed group (HFD group), treatment groups fed 
the HFD for 4  weeks followed by administration of 
CTS at 100  mg/kg/day or 200  mg/kg/day, or a posi-
tive control group treated with simvastatin (10  mg/
kg/day) (Laboratories Fournier S.A., USA) by oral 
gavage for 8  weeks. During the experiment, animal 
body weight was recorded each week, and the con-
trol and HFD groups received equal volumes of saline 
for 8  weeks. After 8  weeks of treatment, all animals 
were sacrificed under chloral hydrate anesthesia and 
blood was collected by cardiac puncture. The main 
part of the visceral fat was removed from each group 
and weighed. The livers and blood plasma were col-
lected and stored at −80°C for further biochemical 
analysis. All animal experiments were conducted in 
accordance with the guidelines (publication number 
85–23, revised 1996) set by the National Institutes of 
Health and the U.S. Department of Agriculture, and 
were approved by the local animal ethics committee of 
Jinan University.
Oral glucose tolerance test (OGTT)
In a separate trial, glucose tolerance was analyzed as pre-
viously described [29]. After 50  days of treatment with 
the HFD, mice were fasted overnight and orally adminis-
tered 2 g/kg glucose. Glucose levels were measured in tail 
blood before and at 30, 60, or 120 min after oral adminis-
tration using a blood glucose monitoring system (ACCU-
CHEK® Active, Roche, Germany). The area under the 
curve (AUC) of blood glucose and time was calculated 
according to the following formula:
where “G” is the blood glucose value.
Insulin tolerance test (ITT)
The ITT was performed as previously described [29]. 
After 60  days of treatment with the HFD, mice were 
fasted overnight and subcutaneously injected with 
0.75  U/kg insulin (Novolin, Novo Nordisk, Denmark). 
Glucose levels were measured from tail blood before and 
15, 30, 60, or 120  min after injection with a blood glu-
cose monitoring system (ACCU-CHEK®Active, Roche, 
Germany). All animals were sacrificed 3  days after the 
ITT. Plasma insulin levels were measured with the insu-
lin radioimmunoassay kit (North Institute of Biologi-
cal Technology, China) according to the manufacturer’s 
instructions.
Measurement of biochemical parameters in plasma
Plasma was separated by centrifuge (Eppendorf 5417R; 
Eppendorf, Germany) at 1,699×g for 15 min at 4°C. The 
triglyceride (TG) and total cholesterol (TC) contents 
in plasma were measured using TG and TC quantifica-
tion kits (Nanjing Jiancheng Bioengineering Institute, 
China). Blood glucose, low-density lipoprotein choles-
terol (LDL-c), and high-density lipoprotein cholesterol 
(HDL-c) levels were determined according to the pro-
tocols of commercially available kits (Nanjing Jiancheng 
Bioengineering Institute). The enzymatic activities of 
plasma aspartate aminotransferase (ALT) and alanine 
aminotransferase (AST) were estimated for assessing 
liver damage using biochemical kits (Nanjing Jiancheng 
Bioengineering Institute).
AUC0−2 h = [(G0 h +G1 h)× 1h+ (G1 h +G2 h)× 1h]/2
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Assay of hepatic levels of free fatty acid (FFA), glutathione 
(GSH), malondialdehyde (MDA), and adenosine 
triphosphatase (ATPase)
The content of FFA in the liver was measured using a 
commercially available kit according to the manufac-
turer’s protocol (Nanjing Jiancheng Bioengineering 
Institute). Hepatic tissues were homogenized (10%, w/v) 
in ice-cold saline (pH 7.4) and centrifuged at 1,699×g 
for 10 min at 4°C. The supernatants were transferred to 
new centrifuge tubes and the MDA, GSH, and ATPase 
contents were measured using biological test kits. Lipid 
peroxidation was estimated by measuring thiobarbituric 
acid-reactive substances (TBARS), and is expressed in 
terms of MDA content according to the manufacturer’s 
protocol. The reagent products were pink in color and 
absorbance was measured using an MK3 microplate 
reader (Thermo Company, MA, USA) at 532 nm. Protein 
content was determined using a protein assay kit (Bio-
Rad Laboratories Inc., USA) to normalize MDA, GSH, 
and ATPase levels.
Oil red O staining of liver
For microscopic analysis of the effect of CTS treat-
ment on hepatic lipid accumulation induced by the HFD, 
0.5 g/100 ml Oil red O (Sigma-Aldrich, St Louis, MO, USA) 
stock solution was prepared in isopropanol. Liver tissues 
(5  μm) were frozen, embedded in optimal cutting tem-
perature medium, stained with Oil red O for 15 min and 
washed, and finally, counterstained with hematoxylin. The 
samples were photographed and examined using a light 
microscope (Olympus, Japan) at a magnification of 400×.
Hepatic lipid content analysis
Liver samples from the five groups were weighed and 
homogenized in tissue lysis buffer containing 20 mM Tris 
HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100; lipid was 
extracted with chloroform/methanol (2:1, v/v).The chlo-
roform layers were separated to measure hepatic TG and 
cholesterol levels using triglyceride and cholesterol kits 
according to the manufacturer’s instructions.
RNA extraction and real‑time reverse transcription 
polymerase chain reaction (RT‑PCR)
Total RNA was extracted from mouse liver tissues using 
Trizol reagent (Invitrogen, Carlsbad, CA, USA) follow-
ing the manufacturer’s directions to determine the effects 
of CTS on TG- and cholesterol-related gene expression. 
Reverse transcription (RT) by total RNA (1 μg), oligo (15) 
dT, and reverse transcriptase was performed using RT 
kits (Takara Biotechnology, Inc., Shiga, Japan) in a final 
volume of 50 μL. PCR primer sequences were designed 
using primer 6.0 software and synthesized by Invitrogen 
Technologies (China). The gene expression levels were 
analyzed in duplicate using a SYBR Green kit (Takara 
Biotechnology, Inc.) on a real-Time PCR System (Light 
Cycler 480, Roche, Switzerland). All the primer lengths 
and annealing temperatures are listed in Table  1. The 
values of the threshold cycle (Ct) were determined using 
Roche analysis software (Light Cycler 480). The relative 
gene expression levels were normalized to the GADPH 
expression level, and the ratios are presented as arbitrary 
units.
Western blotting analysis
Fresh liver tissues were homogenized and lysed in ice-
cold buffer for 30  min, and tissue lysate samples were 
centrifuged at 15,294×g for 20  min at 4°C. The super-
natants were collected and the protein concentrations 
of the lysates were measured using a BCA protein assay 
(Bio-Rad Laboratories Inc.). Twenty micrograms of total 
protein was separated by 8% SDS–polyacrylamide gel 
electrophoresis (SDS-PAGE), electrotransferred to a 
PVDF membrane (Millipore, MA, USA), blocked, and 
immunoblotted with rabbit polyclonal antibodies specific 
for phospho-AMPKα, AMPK, phospho-ACC, and ACC 
(diluted 1:1,000) overnight at 4°C. The blots were incu-
bated with a goat anti-rabbit IgG HRP-conjugated sec-
ondary antibody for 2 h at room temperature after being 
washed. Antibody binding on the PVDF membrane was 
detected using an enhanced chemiluminescence west-
ern blot detection kit (Invitrogen, USA) and Kodak X-ray 
film.
Statistical analysis
Data were analyzed using Origin version 8.0 soft-
ware (Origin Lab, USA) and are presented as the 
Table 1 Primer sequences used for real-time PCR
Genes Primer sequences Length
HMGCS Forward (5′‑3′) GCCGTGAACTGGGTCGAA 77 bp
Reverse (5′‑3′) GCATATATAGCAATGTCTCCTGCAA
ACC Forward (5′‑3′) TGAAGGGCTACCTCTAATG 182 bp
Reverse (5′‑3′) TCACAACCCAAGAACCAC
SCD‑1 Forward (5′‑3′) CCGGAGACCCCTTAGATCGA 190 bp
Reverse (5′‑3′) TAGCCTGTAAAAGATTTCTGCAAACC
SREBP‑2 Forward (5′‑3′)GCGTTCTGGAGACCATGGA 131 bp
Reverse (5′‑3′) ACAAAGTTGCTCTGAAAACAAATCA
SREBP‑1c Forward (5′‑3′)TGTTGGCATCCTGCTATCTG 189 bp
Reverse (5′‑3′) AGGGAAAGCTTTGGGGTCTA
FAS Forward (5′‑3′) GCTGCGGAAACTTCAGGAAAT 84 bp
Reverse (5′‑3′) AGAGACGTGTCACTCCTGGACTT
GAPDH Forward (5′‑3′) AGGTCGGTGTGAACGGATTTG 123 bp
Reverse (5′‑3′) TGTAGACCATGTAGTTGAGGTCA
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mean  ±  standard deviation (SD). Student’s t test was 
used to compare the difference between two groups, and 
one-way analysis of variance (ANOVA) was used to per-
form multiple comparisons. The dose-dependent manner 
was visually determined from the graphs and the ten-
dency of the data. P values less than 0.05 were considered 
statistically significant and a P value less than 0.01 was 
considered very statistically significant; exact P-values 
are shown unless P < 0.001.
Results
CTS content in I. latifolia
There were significant differences in the quantities of 
the 12 main saponins (Fig.  1; Table  2) The contents of 
the 12 main saponins were obtained directly using an 
external standard method. The content of kudinoside D 
(196.68 mg/g) was the highest, followed by those of kudi-
noside A (117.97  mg/g), latifoloside H (104.17  mg/g), 
and kudinoside C (95.57 mg/g). The total amount of the 
twelve main saponins making up CTS was 861.03 mg/g.
CTS reduce the body, liver, and adipose tissue weights 
in mice fed the HFD
Compared with the control group, mice fed the HFD for 
12 weeks exhibited an obvious increase in body, liver, and 
adipose tissue (omental adipose tissue, perirenal adipose 
tissue, epididymal adipose tissue) weights (P  =  0.007, 
P  <  0.001, and P  <  0.001, respectively). A significantly 
lower weight gain was observed in the groups treated 
with CTS-100  mg/kg/day (P  =  0.037) or CTS-200  mg/
kg/day (P = 0.022) than in the HFD group. Adipose tis-
sue weight was slightly lower in the CTS-100  mg/kg/
day group (P = 0.050) than in the HFD group. The liver 
weight and the ratios of liver to body weight in the HFD 
group were markedly higher than those in the other 
groups (P < 0.001 and P < 0.001, respectively). Compared 
with the HFD group, the CTS-200  mg/kg/day group 
showed significantly decreased weight of adipose tis-
sue and ratio of adipose tissue to body weight (P = 0.027 
and P =  0.014, respectively). The HFD induced hepatic 
steatosis and predominantly increased liver, adipose tis-
sue, and body weights. Treatment with CTS inhibited the 
progression of hepatic steatosis and weight gain in the 
liver and adipose tissue (Table 3).
CTS improve plasma lipid parameters in mice fed the HFD
Lipid levels in the blood were measured as shown in 
Table 4. The plasma TG, TC, and LDL-c levels were mark-
edly higher in the HFD group (1.98 ± 0.54, 6.27 ± 1.38, 
and 2.80  ±  0.77  μmol/mL, respectively) compared 
with the control group (1.37  ±  0.46, 2.48  ±  0.23, and 
0.32  ±  0.19  μmol/mL) (P  =  0.050, P  <  0.001, and 
Fig. 1 Total ion chromatograms of CTS from I. latifolia (a) and 12 reference compounds (b) detected in negative ion mode.
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P  <  0.001, respectively). The plasma concentrations of 
TG, TC, and LDL-c were lower in the simvastatin-treated 
group and the CTS-administered groups compared with 
the HFD group, and the levels of TG, TC, and LDL-c in 
mice treated with CTS-200 mg/kg/day were significantly 
lower (P < 0.001, P = 0.018, and P = 0.005, respectively). 
In contrast, CTS-200  mg/kg/d increased the content 
of HDL-c, similar to simvastatin, whereas the HFD 
decreased it (P = 0.006). Our results suggested that CTS 
treatment could reduce fat accumulation in HFD-fed 
C57BL/6 mice.
CTS improve IR in mice
After 50 days of CTS treatment, the untreated HFD-fed 
mice showed a significant increase in blood glucose lev-
els compared with the levels observed in normal controls 
(Fig. 2a). Simvastatin (10 mg/kg/day) and CTS (100 and 
200  mg/kg/day) inhibited this increase in blood glucose 
levels, and decreased the area under the curve (AUC) 
of blood glucose over time compared with the AUC for 
the HFD group (P  =  0.003, P  =  0.031, and P  =  0.018, 
respectively) (Fig.  2b). Compared with the control 
group, the HFD-fed mice exhibited impaired insulin 
Table 2 The chemical structures and contents of 12 triterpenoid saponins in the extract of I. latifolia
No. Constituents Structure Experimental negative  
QTOF‑MS (m/z)/error (ppm)
Weight of concentration  
(mg/g)
Type R1 R2 R3 R4 R5 =
1 Kudinoside O A S4 OH H CH3 S2 12 (13) 1381.6641 [M − H]−/0.31 50.63
2 Kudinoside N A S4 OH CH3 H S2 12 (13) 1381.6632 [M − H]−/0.96 3.45
3 Latifoloside H A S3 OH H CH3 S2 12 (13) 1265.6165 [M + COOH]−/0.56 104.17
4 Latifoloside G A S3 OH CH3 H S2 12 (13) 1265.6173 [M + COOH]−/−0.09 45.76
5 Kudinoside G A S3 OH CH3 H S1 12 (13) 1119.5595 [M + COOH]−/−0.21 65.84
6 Kudinoside C B S4 H OH – – 13 (18) 1133.5375 [M + COOH]−/0.96 95.57
7 Kudinoside A B S3 H OH – – 13 (18) 971.4853 [M + COOH]−/0.45 117.97
8 Kudinoside E B S4 H H – – 11 (12), 13 (18) 1115.5287 [M + COOH]−/−0.68 78.31
9 Kudinoside F B S3 OH H – – 13 (18) 971.4848 [M + COOH]−/0.88 61.16
10 Latifoloside Q A S3 H H CH3 S2 12 (13) 1249.6226 [M + COOH]−/−0.27 33.99
11 Kudinoside D B S3 H H – – 11 (12), 13 (18) 953.4759 [M + COOH]−/−0.82 196.68
12 Ilekudinoside G B S4 H H – – 12 (13) 1117.5430 [M + COOH]−/0.58 7.50
Crude triterpenoid saponins 861.03
Table 3 Effects of CTS on body weight, liver weight, and adipose tissue weight of mice fed with HFD
Adipose tissuea : including omental adipose tissue, perirenal adipose tissue, and epididymal adipose tissue.
Values were expressed as the mean ± SD (n = 10). # P < 0.05, ##P < 0.01, HFD vs. control. △P < 0.05, △△P < 0.01, HFD vs. simvastatin treatment. *P < 0.05, **P < 0.01, 
HFD vs. CTS treatment.
Parameter Control HFD HFD + Simvastatin HFD + CTS‑100 HFD + CTS‑200
Initial body weight (g) 21.10 ± 1.62 21.22 ± 1.21 20.31 ± 1.03 21.56 ± 2.02 21.64 ± 1.36
Final body weight (g) 30.35 ± 3.06 40.39 ± 3.02## 35.63 ± 4.63△ 37.97 ± 4.13* 37.68 ± 2.91*
Body weight gain (g) 9.25 ± 0.91 19.17 ± 0.32# 15.32 ± 0.53△ 16.41 ± 0.44* 14.89 ± 0.46*
Adipose tissuea weight (g) 0.96 ± 0.23 1.67 ± 0.49## 1.24 ± 0.29△ 1.37 ± 0.64 1.43 ± 0.54*
Ratio of adipose tissue and body weight (%) 3.22 ± 0.90 4.29 ± 1.55## 3.51 ± 1.49△ 3.67 ± 2.16 3.84 ± 1.46*
Liver weight (g) 1.45 ± 0.14 2.26 ± 0.17## 2.02 ± 0.39△△ 2.15 ± 0.22 2.09 ± 0.39**
Ratio of liver and body weight (%) 4.81 ± 0.60 5.74 ± 0.71## 5.50 ± 1.47△ 5.70 ± 0.70 5.63 ± 1.30*
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tolerance (P  <  0.001). Simvastatin or CTS-200  mg/kg/
day improved insulin tolerance (P = 0.004 and P = 0.006, 
respectively) (Fig.  2c, d). Furthermore, CTS-200  mg/
kg/day significantly reduced the elevated fasting blood 
insulin level in HFD-fed mice (P  <  0.001), while fasting 
blood glucose was not affected by CTS-200  mg/kg/d 
(P  =  0.412) (Table  4). Hepatic FFA content and Ca2+-
Mg2+-ATPase activity were significantly increased in the 
HFD-fed mice compared with those in normal controls 
(P < 0.001 and P = 0.048, respectively). Further, the FFA 
Table 4 Effects of CTS on plasma parameters in mice fed with HFD
Values were expressed as the mean ± SD (n = 10). # P < 0.05, ##P < 0.01, HFD vs. control. △P < 0.05,△△P < 0.01, HFD vs. simvastatin treatment. *P < 0.05, **P < 0.01, 
HFD vs. CTS treatment.
Parameter Control HFD HFD + Simvastatin HFD + CTS‑100 HFD + CTS‑200
TG (mmol/L) 1.37 ± 0.46 1.98 ± 0.54# 1.04 ± 0.26△△ 1.29 ± 0.34** 1.21 ± 0.15**
TC (mmol/dL) 2.48 ± 0.23 6.27 ± 1.38## 5.27 ± 0.20△ 5.79 ± 0.60 5.59 ± 0.70*
LDL‑C (mmol/dL) 0.32 ± 0.19 2.80 ± 0.77## 1.95 ± 0.45△ 2.53 ± 0.28 2.09 ± 0.39**
HDL‑c (mmol/dL) 1.33 ± 0.46 0.95 ± 0.10# 1.77 ± 0.66△ 1.25 ± 0.30** 1.36 ± 0.08**
Glucose (mmol/L) 8.61 ± 1.34 9.99 ± 1.56## 8.76 ± 1.43△ 9.80 ± 1.53 9.60 ± 1.21
Insulin (nmol/L) 22.63 ± 5.93 36.56 ± 7.77## 25.53 ± 7.03△ 26.43 ± 9.71* 24.52 ± 6.20**
Fig. 2 Effects of CTS on the oral glucose tolerance test (GTT) and insulin tolerance test (ITT). The high‑fat diet (HFD)‑fed mice were fasted overnight 
and treated with oral intragastric administration of 2 g/kg glucose or a subcutaneous injection of 0.75 U/kg insulin. Simvastatin and CTS reduced 
the glucose curve induced by glucose and insulin, leading to the eventual improvement in glucose tolerance and insulin resistance. a Effects of CTS 
on glucose tolerance in blood. b Effects of CTS on insulin tolerance in blood. c, d Quantitative analysis of the area under the curve (AUC) from the 
GTT and ITT. The results are represented as the mean ± SD (n = 10).
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content and ATPase activity in the liver were highly sig-
nificantly lower in mice treated with CTS-200 mg/kg/day 
compared with HFD-fed mice (P < 0.001 and P = 0.001, 
respectively) (Table 5).
CTS protect mouse liver against oxidative stress‑mediated 
injury induced by lipid overload
The hepatic TBARS content was determined to evalu-
ate lipid peroxidation levels in the liver and the anti-
oxidative status (Table  5). Both results showed that 
CTS attenuated oxidative stress in the liver. The level 
of MDA in the liver was four times higher in the HFD 
group than in the untreated group (P < 0.001), and CTS-
100 mg/kg/d markedly reduced the level of MDA (from 
3.19 ± 0.33 to 1.68 ± 0.54). The level of GSH in the liver 
was lower in the HFD group than in the control group 
(P  <  0.001). After 8  weeks of treatment, CTS (100 and 
200  mg/kg/day) significantly increased the GSH level 
in the liver to a level comparable to that in the control 
group (P  <  0.001 and P  <  0.001, respectively). Plasma 
ALT and AST activities in different groups were exam-
ined to determine whether treatment with CTS could 
improve the HFD-induced liver injury. The activity of 
plasma ALT in the HFD group was significantly higher 
than that in the control group, and both simvastatin and 
CTS-200 mg/kg/d decreased ALT activity (P < 0.001 and 
P  <  0.001, respectively). However, there was no signifi-
cant difference in the level of plasma AST among these 
groups, except for that in the simvastatin group (Table 6). 
Hepatic lipids were measured by Oil O red staining and 
TG content analysis. HFD induced the formation of lipid 
droplets, which was ameliorated by simvastatin and CTS 
treatments (Fig.  3). These results suggested that CTS 
treatment dose-dependently protected against liver dam-
age by suppressing hepatic fat accumulation.
CTS activate AMPK phosphorylation and inhibit mRNA 
expression of SREBPs and their target genes
HFD-fed mice showed inhibition of AMPKα (Thr172) 
and ACC protein phosphorylation in the liver (P < 0.001 
and P = 0.001, respectively), but AMPKα and ACC phos-
phorylation was restored after treatment with CTS-
200  mg/kg/day for 8  weeks (P  =  0.011 and P  <  0.001, 
respectively). On the other hand, the mRNA levels of 
SREBP-1c, FAS, SCD-1, and ACC were significantly 
inhibited in the CTS-treated group (P = 0.013, P = 0.011, 
P = 0.014, and P = 0.023, respectively). Meanwhile, the 
expression of the genes in the cholesterol synthetic path-
way, such as SREBP-2 and HMGCS, was significantly 
attenuated in the liver in comparison to that in the HFD-
fed group (P = 0.007 and P = 0.010, respectively) (Fig. 4). 
Activation of the AMPK-mediated SREBP signaling path-
way by CTS might be a potential mechanism underlying 
the suppression of hepatic fat accumulation.
Discussion
We showed that orally administered CTS (100 and 
200 mg/kg/day) from I. latifolia could alleviate NAFLD in 
HFD-fed mice, and elucidated its underlying mechanisms 
of suppression of fat accumulation via AMPK pathway 
activation, to reduce body weight gain, hyperlipidemia, 
and IR in HFD-fed mice. The depletion of glutathione 
levels and lipid peroxidation in HFD-fed mice were 
inhibited by administration of CTS. ALT activity and his-
tologic evidence in the liver showed that CTS treatment 
prevented liver injury caused by lipid accumulation. CTS 
Table 5 Effects of CTS on FFA, MDA, GSH and ATPase in the livers of mice fed with HFD
Values were expressed as the mean ± SD (n = 10). # P < 0.05, ##P < 0.01, HFD vs. control. △P < 0.05, △△P < 0.01, HFD vs. simvastatin treatment. *P < 0.05, **P < 0.01, 
HFD vs. CTS treatment.
Parameter Control HFD HFD + Simvastatin HFD + CTS‑100 HFD + CTS‑200
FFA (μmol/g protein) 61.05 ± 12.49 94.70 ± 15.63## 91.73 ± 13.50△ 93.89 ± 10.81* 79.87 ± 11.18**
MDA (nmol/mg protein) 0.69 ± 0.34 3.19 ± 0.33## 1.88 ± 0.44△△ 1.68 ± 0.54** 1.50 ± 0.38**
GSH (μg/mg protein) 2.65 ± 0.53 1.05 ± 0.24## 2.80 ± 0.59△△ 2.55 ± 0.65** 2.61 ± 0.50**
Na+‑K+‑ATPase (mmol pi/g/h) 1.55 ± 0.19 1.79 ± 018# 1.57 ± 0.26△ 1.68 ± 0.10 1.60 ± 0.26*
Ca2+‑Mg2+‑ATPase (mmol pi/g/h) 1.65 ± 0.13 1.76 ± 0.11# 1.31 ± 0.14△ 1.55 ± 0.14** 1.42 ± 0.31**
Table 6 Effects of CTS on plasma ALT and AST activities in mice fed with HFD
Values were expressed as the mean ± SD (n = 10). # P < 0.05, ##P < 0.01, HFD vs. control. △P < 0.05,△△P < 0.01, HFD vs. simvastatin treatment. *P < 0.05, **P < 0.01, 
HFD vs. CTS treatment.
Parameter Control HFD HFD + Simvastatin HFD + CTS‑100 HFD + CTS‑200
ALT (KAIU/L) 43.15 ± 3.98 62.61 ± 14.81## 51.34 ± 15.81△△ 50.94 ± 15.95** 40.74 ± 7.90**
AST (KAIU/L) 104.85 ± 26.20 101.74 ± 22.86 127.65 ± 11.83△△ 96.24 ± 10.18 98.87 ± 12.61
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could activate AMPK and suppress expression of SREBPs 
and their target genes.
In previous studies I. latifolia was shown to exhibit 
anti-inflammatory and antioxidant effects and improve 
lipid metabolism [30, 31]. The water extract of I. latifolia 
inhibited hyperglycemia in rats with epinephrine-induced 
hyperglycemia [32], and increased the contractility and 
decreased the frequency of contraction in an isolated rat 
heart perfusion system by inhibiting Na+/K+-ATPase 
activities [33]. Triterpenoid saponins such as ilekudino-
side N and ilekudinoside Q from the aqueous extract of 
I. kudingcha reduced intracellular TC and TG contents in 
macrophages [34]. In addition, the CTS from the aqueous 
extract could significantly improve metabolic disorders in 
NAFLD mice [35].
In this study, an HFD-induced NAFLD mouse model 
was established according to previous research [29]. The 
HFD-fed group had higher body weight, fat accumulation 
Fig. 3 Effects of CTS on liver injury and hepatic lipid content in HFD‑fed mice. a Oil red O staining (×400) of the liver sections. Arrows indicate 
steatosis induced by HFD feeding. b The quantitative analysis of triglyceride (TG) and total cholesterol (TC) contents in livers. The HFD‑fed mice 
were administered two concentrations of CTS (100 and 200 mg/kg/days) or the positive control simvastatin 10 mg/kg/d for 8 weeks. The results are 
represented as the mean ± SD (n = 10).
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Fig. 4 Effects of CTS on gene and protein expression of lipogenic and cholesterol‑related synthetic enzymes. a The gene expression of lipogenic 
enzymes (SREBP‑1c SCD1, ACC, FAS) in the livers of mice was suppressed by CTS‑200 mg/kg/days. b The gene expression of cholesterol related syn‑
thetic enzymes (SREBP‑2, HMGCS) in the livers of mice was suppressed by CTS‑200 mg/kg/day. c Immunoblot analysis of phospho‑AMPKα (Thr172), 
AMPK, phospho‑ACC, and ACC protein. The protein levels are expressed as fold of control. All data were expressed as the mean ± SD (n = 10) of 
three independent experiments.
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in liver, and plasma levels of glucose and insulin com-
pared with those in mice fed normal diets. Additionally, 
HFD caused a lipid metabolism disorder and disrupted 
the homeostasis of the liver oxidative state, which is an 
important characteristic in the development of NAFLD. 
Oral administration of CTS strongly prevented the devel-
opment of NAFLD by significantly decreasing body and 
adipose tissue weights. Lipid accumulation in the liver 
frequently promoted the release of MDA, which diffused 
into other sites and favored oxidative stress [36, 37]. The 
increase in MDA content and decrease in GSH level 
could contribute to apoptosis and nuclear-mitochondrial 
DNA damage in NASH by producing reactive oxygen 
species (ROS) [37]. Our results demonstrated that CTS 
administration could reduce MDA content and restore 
GSH levels in the livers of HFD-fed mice. Plasma ALT 
levels indicated a protective effect of CTS on the liver.
IR is involved in the pathological process of NAFLD [38, 
39]. Adipose tissue is insensitive to the anti-lipolytic effects 
of insulin in IR conditions, and the influx of exogenous 
FFA to the liver is increased. Circulating FFAs promote 
the production of intracellular metabolites (diacylglyc-
erol), and produce dysfunctional cellular glucose [40]. In 
contrast, other studies have reported that IR and hyper-
insulinemia are linked to the impairment of adenosine 
triphosphate (ATP) homeostasis [41, 42]. In the present 
study, the levels of insulin in HFD-fed mice were reduced 
significantly by CTS administration. Furthermore, CTS 
could improve HFD-induced glucose and IR. Moreover, 
CTS significantly reduced the levels of hepatic FFA and 
the activities of Na+-K+-ATPase and Ca2+-Mg2+-ATPase. 
These results suggested that CTS prevented pathological 
development of NAFLD by improving IR.
AMPK, an important energy sensor for cellular energy 
homeostasis, is recognized as a potential therapeutic 
target for the prevention and treatment of metabolic 
syndrome [43, 44]. The activation of AMPK in the liver 
could not only inhibit lipogenesis and gluconeogen-
esis but also stimulate fatty acid oxidation [45]. Natural 
products and drugs, such as resveratrol and metformin, 
could inhibit lipogenesis and eliminate hepatic steatosis 
in HFD-induced fatty liver by activating AMPK [46, 47]. 
Activated AMPK could bind phosphorylated SREBP-1c 
and SREBP-2, negatively regulating their proteolytic pro-
cessing and elevating the expression levels of their target 
genes (ACC, FAS, SCD1, and HMGCS) in the livers of IR 
mice [42, 48].The phosphorylation of AMPKα was acti-
vated by CTS treatment and the mRNA expression levels 
of SREBP-1c, FAS, SCD1, and ACC were reduced in the 
CTS-treated group. Meanwhile, CTS also suppressed the 
mRNA expression of SREBP2 and HMGCR, which are 
responsible for cholesterol biosynthesis [49]. CTS inhib-
ited lipogenic synthesis and improved IR in HFD-fed 
mice by upregulating AMPK activation and suppressing 
the transcription of SREBPs and their target genes.
Conclusion
CTS from I. latifolia improved IR and liver injury in 
HFD-fed mice, and attenuated NAFLD via the activa-
tion of AMPK and inhibition of the gene expression of 
SREBPs and some of their target molecules.
Abbreviations
CTS: crude triterpenoid saponins; HFD: high‑fat diet; NAFLD: non‑alcoholic 
fatty liver disease; AMPK: AMP‑activated protein kinase; NASH: non‑alcoholic 
steatohepatitis; T2DM: type 2 diabetes mellitus; UHPLC‑Q‑TOF–MS: ultra‑high 
performance liquid chromatography quadrupole time‑of‑flight tandem mass 
spectrometry; MCAO: middle cerebral artery occlusion; TBARS: thiobarbituric 
acid‑reactive substances; RT‑PCR: real‑time reverse transcription polymerase 
chain reaction; AUC: area under the curve; SDS‑PAGE: SDS‑polyacrylamide gel 
electrophoresis; TG: triglycerides; ACC‑1: CoA carboxylase‑1; FAS: fatty acid 
synthase; SCD‑1: stearoyl‑CoA desaturase; SREBP‑1c: sterol regulatory element‑
binding protein‑1c; SREBP‑2: sterol regulatory element‑binding protein 2; 
HMGCS: hydroxymethylglutaryl coenzyme A synthase; OGTT: oral glucose tol‑
erance test; ITT: insulin tolerance test; TC: Total cholesterol; LDL‑c: low‑density 
lipoprotein cholesterol; HDL‑c: high‑density lipoprotein cholesterol; ALT: 
aspartate aminotransferase; AST: alanine aminotransferase; FFA: free fatty acid; 
GSH: glutathione; MDA: malondialdehyde; ATPase: adenosine triphosphatase; 
ROS: reactive oxygen species; IR: insulin resistance.
Authors’ contributions
WCY, MML and YW conceived and designed the study. RBF, CLF, MML, QL 
and ZL performed the experiments and collected the data. RBF, CLF, MML 
wrote the manuscript. WZ, YLL and WT revised the work. All authors read and 
approved the final manuscript.
Author details
1 College of Pharmacy, Jinan University, Guangzhou 510632, People’s Republic 
of China. 2 Guangdong Province Key Laboratory of Pharmacodynamic Constit‑
uents of TCM and New Drugs Research, Jinan University, Guangzhou 510632, 
People’s Republic of China. 3 Guangzhou Jinan Biomedicine Research 
and Development Center, National Engineering Research Center of Genetic 
Medicine, Jinan University, Guangzhou 510632, People’s Republic of China. 
Acknowledgements
This work was supported financially by the Natural Science Foundations of 
China (81202427, 81302654), Key Laboratory for the Chemistry and Molecular 
Engineering of Medicinal Resources (Guangxi Normal University), Ministry 
of Education of China (No. CMEMR2013‑B04), Foundation for Distinguished 
Young Talents in Higher Education of Guangdong, China (LYM11024) and 
the Science and Technology Planning Project of Guangdong Province (No. 
2012A080204005) and the Project of Guangdong Provincial Administration of 
traditional Chinese medicine (No. 20121161).
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 29 August 2014   Accepted: 28 July 2015
References
 1. Petta S, Amato M, Di Marco V, Cammà C, Pizzolanti G, Barcellona M et al 
(2012) Visceral adiposity index is associated with significant fibrosis in 
patients with non‑alcoholic fatty liver disease. Aliment Pharm Therap 
35:238–247
Page 12 of 13Feng et al. Chin Med  (2015) 10:23 
 2. Wong RJ, Ahmed A (2014) Obesity and non‑alcoholic fatty liver disease: 
disparate associations among Asian populations. World J Hepatol 
6:263–273
 3. Cauchy F, Fuks D, Zarzavadjian Le Bian A, Belghiti J, Costi R (2014) Meta‑
bolic syndrome and non‑alcoholic fatty liver disease in liver surgery: the 
new scourges? World J Hepatol 6:306–314
 4. Wu CL, Zhao SP, Yu BL (2015) Intracellular role of exchangeable apoli‑
poproteins in energy homeostasis, obesity and non‑alcoholic fatty liver 
disease. Biol Rev 90:367–376
 5. Marzuillo P, Del Giudice EM, Santoro N (2014) Pediatric non‑alcoholic 
fatty liver disease: new insights and future directions. World J Hepatol 
6:217–225
 6. Ozturk ZA, Kadayifci A (2014) Insulin sensitizers for the treatment of non‑
alcoholic fatty liver disease. World J Hepatol 6:199–206
 7. Daemen S, Kutmon M, Evelo CT (2013) A pathway approach to investi‑
gate the function and regulation of SREBPs. Genes Nutr 8:289–300
 8. Xiaoli YF (2013) Mediating lipid biosynthesis: implications for cardiovascu‑
lar disease. Trends Cardiovasc Med 23:269–273
 9. Faust PL, Kovacs WJ (2014) Cholesterol biosynthesis and ER stress in 
peroxisome deficiency. Biochimie 98:75–85
 10. Kim YW, Kim YM, Yang YM, Kim TH, Hwang SJ, Lee JR et al (2010) Inhibi‑
tion of SREBP‑1c‑mediated hepatic steatosis and oxidative stress by 
sauchinone, an AMPK‑activating lignan in Saururus chinensis. Free Radi‑
cal Bio Med 48:567–578
 11. Lee HI, Yun KW, Seo KI, Kim MJ, Lee MK (2014) Scopoletin prevents 
alcohol‑induced hepatic lipid accumulation by modulating the AMPK‑
SREBP pathway in diet‑induced obese mice. Metabolism 63:593–601
 12. Lu J, Huang G, Hu S, Wang Z, Guan S (2014) 1,3‑Dichloro‑2‑propanol 
induced hyperlipidemia in C57BL/6J mice via AMPK signaling pathway. 
Food Chem Toxicol 64:403–409
 13. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B et al (2011) AMPK 
phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis 
and atherosclerosis in diet‑induced insulin‑resistant mice. Cell Metab 
13:376–388
 14. Li L, Xu LJ, Ma GZ, Dong YM, Peng Y, Xiao PG (2013) The large‑leaved 
Kudingcha (Ilex latifolia Thunb and Ilex kudingcha C.J. Tseng): a traditional 
Chinese tea with plentiful secondary metabolites and potential biological 
activities. J Nat Med 67:425–437
 15. Huang J, Wang X, Ogihara Y, Shimizu N, Takeda T, Akiyama T (2001) 
Latifolosides I and J, two new triterpenoid saponins from the bark of Ilex 
latifolia. Chem Pharm Bull (Tokyo) 49:239–241
 16. Chen Y, Li K, Xie T (1994) Hypotensive action of the extract of Kudingcha 
dongqingye (Ilex kudingcha). Chin Tradit Herb Drugs 26:250–252
 17. Wang CQ, Wang L, Fan CL, Zhang DM, Huang XJ, Jiang RW et al (2012) 
Ilelic acids A and B, two unusual triterpenes with a seven‑membered ring 
from Ilex latifolia. Org Lett 14:4102–4105
 18. Zuo WJ, Dai HF, Chen J, Chen HQ, Zhao YX, Mei WL et al (2011) Triterpenes 
and triterpenoid saponins from the leaves of Ilex kudingcha. Planta Med 
77:1835–1840
 19. She GM, Wang D, Zeng SF, Yang CR, Zhang YJ (2008) New phenylethanoid 
glycosides and sugar esters from Ku‑Ding‑Cha, a herbal tea Produced 
from Ligustrum purpurascens. J Food Sci 73:476–481
 20. Hao D, Gu X, Xiao P, Liang Z, Xu L, Peng Y (2013) Research progress in 
the phytochemistry and biology of Ilex pharmaceutical resources. Acta 
Pharmaceutica Sinica B 3:8–19
 21. Kim JY, Jeong HY, Lee HK, Yoo JK, Bae K, Seong YH (2011) Protective effect 
of Ilex latifolia, a major component of “kudingcha”, against transient 
focal ischemia‑induced neuronal damage in rats. J Ethnopharmacol 
133:558–564
 22. Cignarella A, Fan S, Zhang Y, Hu N, Sun Q, Ding X et al (2012) Extract 
of kuding tea prevents high‑fat diet‑induced metabolic disorders in 
C57BL/6 mice via liver X receptor (LXR) β antagonism. PLoS One 7:1–12
 23. Fan J, Wu Z, Zhao T, Sun Y, Ye H, Xu R et al (2014) Characterization, antioxi‑
dant and hepatoprotective activities of polysaccharides from Ilex latifolia 
Thunb. Carbohyd Polym 101:990–997
 24. Nishimura K, Fukuda T, Miyase T, Noguchi H, Chen XM (1999) Activity‑
guided isolation of triterpenoid acyl CoA cholesteryl acyl transferase 
(ACAT) inhibitors from Ilex kudingcha. J Nat Prod 62:1061–1064
 25. Nishimura K, Miyase T, Noguchi H (1999) Triterpenoid saponins from Ilex 
kudingcha. J Nat Prod 62:1128–1133
 26. Fan C, Fan L, Zhang X, Wang Y, Zhang J, Ye W (2010) Triterpenoid saponins 
from the leaves of Ilex latifolia. Chin Pharm J. 45:1228–1232
 27. Ouyang M, Wang H, Liu Y, Yang C (1997) Triterpenoid saponins from the 
leaves of Ilex latifolia. Phytochemistry 45:1501–1505
 28. Fan C, Deng J, Yang Y, Liu J, Wang Y, Zhang X et al (2013) Multi‑
ingredients determination and fingerprint analysis of leaves from Ilex 
latifolia using ultra‑performance liquid chromatography coupled with 
quadrupole time‑of‑flight mass spectrometry. J Pharm Biomed Anal 
84:20–29
 29. Tang J, Li J, Qi W, Qiu W, Li P, Li B et al (2011) Inhibition of SREBP by a small 
molecule, betulin, improves hyperlipidemia and insulin resistance and 
reduces atherosclerotic plaques. Cell Metab 13:44–56
 30. Li L, Peng Y, Ma G, He C, Feng Y, Lei Q et al (2012) Quantitative analysis of 
five kudinosides in the large‑leaved Kudingcha and related species from 
the genus Ilex by UPLC‑ELSD. Phytochem Anal 23:677–683
 31. Hu T, He XW, Jiang JG, Xu XL (2014) Efficacy evaluation of a Chinese bitter 
tea (Ilex latifolia Thunb.) via analyses of its main components. Food Funct 
5:876–881
 32. Qu LZ, Lu T, Lu PJ, Xi J (1999) The effect of Kudingcha on epinephrine 
hyperglycemia rats. Tradit Chin Drug Res Clin Pharmacol 10:279–280
 33. Woo AY, Jiang JM, Chau CF, Waye MM, Cheung WT, Kwan HS et al 
(2001) Inotropic and chronotropic actions of Ilex latifolia inhibition 
of adenosine‑5′‑triphosphatases as a possible mechanism. Life Sci 
68:1259–1270
 34. Zheng J, Tang L, Xian XD, Zhou SX, Shi HM, Jiang Y et al (2009) Inhibitory 
effect of triterpenoid saponins from the leaves of Ilex kudingcha on 
aggregated LDL‑induced lipid deposition in macrophages. Planta Med 
75:1410–1414
 35. Pan H, Liao Z, Ying Q, Tian J, Xu Y (2004) Study on lipid‑depressing 
function of kuding tea prepared from Ilex latifolia Thunb leaves. J Tea Sci 
24:49–52
 36. Ferro E, Visalli G, Civa R, La Rosa MA, Randazzo Papa G, Baluce B et al 
(2012) Oxidative damage and genotoxicity biomarkers in transfused and 
untransfused thalassemic subjects. Free Radic Biol Med 53:1829–1837
 37. Takaki A, Kawai D, Yamamoto K (2013) Multiple hits, including oxidative 
stress, as pathogenesis and treatment target in non‑alcoholic steato‑
hepatitis (NASH). Int J Mol Sci 14:20704–20728
 38. Milic S, Lulic D, Stimac D (2014) Non‑alcoholic fatty liver disease and 
obesity: biochemical, metabolic and clinical presentations. World J Gas‑
troenterol 20:9330–9337
 39. Pala L, Barbaro V, Dicembrini I, Rotella CM (2014) The therapy of insulin 
resistance in other diseases besides type 2 diabetes. Eat Weight Disord. 
19:275–283
 40. Tarantino G, Saldalamacchia G, Conca P, Arena A (2007) Non‑alcoholic 
fatty liver disease: further expression of the metabolic syndrome. J Gas‑
troenterol Hepatol 22:293–303
 41. Hui E, Xu A, Bo Yang H, Lam KS (2013) Obesity as the common soil of non‑
alcoholic fatty liver disease and diabetes: role of adipokines. J Diabetes 
Investig 4:413–425
 42. Pasarin M, Abraldes JG, Rodriguez‑Vilarrupla A, La Mura V, Garcia‑Pagan 
JC, Bosch J (2011) Insulin resistance and liver microcirculation in a rat 
model of early NAFLD. J Hepatol 55:1095–1102
 43. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP‑activated protein 
kinase: ancient energy gauge provides clues to modern understanding of 
metabolism. Cell Metab 1:15–25
 44. Grahame Hardie D (2014) AMP‑activated protein kinase: a key regula‑
tor of energy balance with many roles in human disease. J Intern Med 
276:543–559
 45. Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L et al 
(2006) Activation of AMP‑activated protein kinase in the liver: a new 
strategy for the management of metabolic hepatic disorders. J Physiol 
574:41–53
 46. Jeon BT, Jeong EA, Shin HJ, Lee Y, Lee DH, Kim HJ et al (2012) Resveratrol 
attenuates obesity‑associated peripheral and central inflammation 
and improves memory deficit in mice fed a high‑fat diet. Diabetes 
61:1444–1454
 47. Caton P, Kieswich J, Yaqoob M, Holness M, Sugden M (2011) Metformin 
opposes impaired AMPK and SIRT1 function and deleterious changes 
in core clock protein expression in white adipose tissue of genetically‑
obese db/db mice. Diabetes Obes Metab 13:1097–1104
Page 13 of 13Feng et al. Chin Med  (2015) 10:23 
 48. Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Harima M, Suzuki K 
et al (2013) Curcumin decreases renal triglyceride accumulation through 
AMPK‑SREBP signaling pathway in streptozotocin‑induced type 1 dia‑
betic rats. J Nutr Biochem 24:796–802
 49. Min H‑K, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J et al (2012) 
Increased hepatic synthesis and dysregulation of cholesterol metabolism 
is associated with the severity of nonalcoholic fatty liver disease. Cell 
Metab 15:665–674
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
